Baupost Group’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Baupost Group’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-67,296	Closed	-$243K	–	29
2023 Q4	$243K	Hold	67,296	–	–	0.01%	23
2023 Q3	$349K	Hold	67,296	–	–	0.01%	32
2023 Q2	$574K	Sell	67,296 -4	-0%	-$41	0.01%	29
2023 Q1	$793K	Buy	67,300 +33,333	+98%	+$442K	0.01%	30
2022 Q4	$489K	Sell	33,967 -3,470	-9%	-$116K	0.01%	33
2022 Q3	$1.88M	Hold	37,437	–	–	0.03%	35
2022 Q2	$3.19M	Hold	37,437	–	–	0.05%	39
2022 Q1	$5.65M	Sell	37,437 -305	-0.8%	-$70.4K	0.06%	42
2021 Q4	$11.3M	Sell	37,742 -2,530	-6%	-$970K	0.11%	39
2021 Q3	$15.7M	Hold	40,272	–	–	0.14%	41
2021 Q2	$16.7M	Hold	40,272	–	–	0.14%	42
2021 Q1	$18.9M	Buy	+40,272	New	+$20.5M	0.15%	44

Other funds holding FNCH

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Baupost Group's FNCH Position: Q1 2024 in Review

Baupost Group sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2024, closing a stake of 67,296 shares — an estimated $243K sold.

Baupost Group first reported a position in FNCH in Q1 2021 and held it in 12 quarters. The position peaked at $18.9M in Q1 2021. 11 funds tracked by Wall St. Rank hold FNCH as of Q1 2024.

Baupost Group reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Baupost Group sold 67,296 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2024, an estimated $243K.
Baupost Group first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
Baupost Group's Finch Therapeutics Group, Inc. Common Stock position peaked at $18.9M in Q1 2021.
11 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2024.

Based on Baupost Group's 13F filing for Q1 2024, filed 14 May 2024.